Clinical trial
A Phase 1 Study of CNTO 328 (Siltuximab) in Combination With Bortezomib and Dexamethasone for Patients With Relapsed or Refractory Multiple Myeloma
NCT01309412 is registered in ClinicalTrials.gov with Janssen Pharmaceutical K.K. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Study of CNTO 328 (Siltuximab) in Combination With Bortezomib and Dexamethasone for Patients With Relapsed or Refractory Multiple Myeloma
- Lead sponsor
- Janssen Pharmaceutical K.K.
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- January 31, 2011
- Completion date
- December 31, 2012
- Enrollment
- 9 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.